Abstract
Objective: A systematic review of the prevalence and prognosis of posttransplant diabetes mellitus (PTDM) following the transplantation of heart, lung, liver and kidney and a metaanalysis of randomised studies of glucose-lowering treatment is reported.
Methods: We searched for publications on solid organ transplants and PTDM in relation to the risk and total mortality of PTDM and randomized controlled trials aiming at reducing glucose levels.
Results: PTDM prevalence one year after transplantation was reported to be 9-40%. Ten years after transplantation, 60-85% of people without PTDM and 30-76% of people with PTDM were alive. Following kidney transplantation, we identified six randomized controlled trials on the treatment of PTDM. Intervention ranged from 3 to 12 months. Four studies used intervention with oral glucose-lowering drugs, one used dietician appointments and exercise, and one used insulin treatment. Among the intermediate results reported, a reduction in HbA1c of 2.7 mmol/mol, and an increase in the odds ratio of serious adverse events of 3.0 was significant.
Conclusion: In conclusion, information on the prevalence and effect on survival of PTDM is heterogeneous, and the randomized studies on the effect of treatment available are short and lack information on clinically important endpoints, such as mortality or morbidity.
[1]
Sharif A, Hecking M, de Vries AP, et al. AP, et al. Proceedings from an international consensus meeting on post transplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 14(9): 1992-2000.
[http://dx.doi.org/10.1111/ajt.12850]
[http://dx.doi.org/10.1111/ajt.12850]
[2]
Hornum M, Lindahl JP, von Zur-Mühlen B, Jenssen T, Feldt-Rasmussen B. Diagnosis, management and treatment of glucometabolic disorders emerging after kidney transplantation. Transpl Int 2013; 26(11): 1049-60.
[http://dx.doi.org/10.1111/tri.12112] [PMID: 23634804]
[http://dx.doi.org/10.1111/tri.12112] [PMID: 23634804]
[3]
Conte C, Maggiore U, Cappelli G, et al. Management of metabolic alterations in adult kidney transplant recipients: A joint position statement of the Italian Society of Nephrology (SIN), the Italian Society for Organ Transplantation (SITO) and the Italian Diabetes Society (SID). Nutr Metab Cardiovasc Dis 2020; 30(9): 1427-41.
[http://dx.doi.org/10.1016/j.numecd.2020.05.004] [PMID: 32605884]
[http://dx.doi.org/10.1016/j.numecd.2020.05.004] [PMID: 32605884]
[4]
Jenssen TG, Hartmann A. Post-transplant diabetes mellitus in people with solid organ transplants. Nature Rev Endocrinol 2019; 15(3): 172-88.
[http://dx.doi.org/10.1038/s41574-018-0137-7]
[http://dx.doi.org/10.1038/s41574-018-0137-7]
[5]
Rodríguez-Rodríguez AE, Porrini E, Hornum M, et al. Post-transplant diabetes mellitus and prediabetes in renal transplant recipients: an update. Nephron J 2021; 145(4): 317-29.
[http://dx.doi.org/10.1159/000514288] [PMID: 33902027]
[http://dx.doi.org/10.1159/000514288] [PMID: 33902027]
[6]
Hornum M, Jørgensen KA, Hansen JM, et al. New-onset diabetes mellitus after kidney transplantation in Denmark. Clin J Am Soc Nephrol 2010; 5(4): 709-16.
[http://dx.doi.org/10.2215/CJN.05360709] [PMID: 20167685]
[http://dx.doi.org/10.2215/CJN.05360709] [PMID: 20167685]
[7]
Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: An analysis from the Whitehall II study. Lancet 2009; 373(9682): 2215-21.
[http://dx.doi.org/10.1016/S0140-6736(09)60619-X] [PMID: 19515410]
[http://dx.doi.org/10.1016/S0140-6736(09)60619-X] [PMID: 19515410]
[8]
Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med 2015; 373(18): 1720-32.
[http://dx.doi.org/10.1056/NEJMoa1504347] [PMID: 26510021]
[http://dx.doi.org/10.1056/NEJMoa1504347] [PMID: 26510021]
[9]
Read SH, Fischbacher CM, Colhoun HM, et al. Trends in incidence and case fatality of acute myocardial infarction, angina and coronary revascularisation in people with and without type 2 diabetes in Scotland between 2006 and 2015. Diabetologia 2019; 62(3): 418-25.
[http://dx.doi.org/10.1007/s00125-018-4796-7] [PMID: 30656362]
[http://dx.doi.org/10.1007/s00125-018-4796-7] [PMID: 30656362]
[10]
Porrini E, Díaz JM, Moreso F, et al. Prediabetes is a risk factor for cardiovascular disease following renal transplantation. Kidney Int 2019; 96(6): 1374-80.
[http://dx.doi.org/10.1016/j.kint.2019.06.026] [PMID: 31611066]
[http://dx.doi.org/10.1016/j.kint.2019.06.026] [PMID: 31611066]
[11]
Valderhaug TG, Hjelmesæth J, Hartmann A, et al. The association of early post-transplant glucose levels with long-term mortality. Diabetologia 2011; 54(6): 1341-9.
[http://dx.doi.org/10.1007/s00125-011-2105-9] [PMID: 21409415]
[http://dx.doi.org/10.1007/s00125-011-2105-9] [PMID: 21409415]
[12]
Eide IA, Halden TAS, Hartmann A, Dahle DO, Åsberg A, Jenssen T. Associations between posttransplantation diabetes mellitus and renal graft survival. Transplantation 2017; 101(6): 1282-9.
[http://dx.doi.org/10.1097/TP.0000000000001259] [PMID: 27362306]
[http://dx.doi.org/10.1097/TP.0000000000001259] [PMID: 27362306]
[13]
Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020; 63(2): 221-8.
[http://dx.doi.org/10.1007/s00125-019-05039-w] [PMID: 31857443]
[http://dx.doi.org/10.1007/s00125-019-05039-w] [PMID: 31857443]
[14]
Lo C, Toyama T, Oshima M, et al. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. Cochrane Libr 2020; 2020(8)CD009966
[http://dx.doi.org/10.1002/14651858.CD009966.pub3] [PMID: 32803882]
[http://dx.doi.org/10.1002/14651858.CD009966.pub3] [PMID: 32803882]
[15]
Oikonomaki D, Dounousi E, Duni A, Roumeliotis S, Liakopoulos V. Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2021; 172108604
[http://dx.doi.org/10.1016/j.diabres.2020.108604] [PMID: 33338553]
[http://dx.doi.org/10.1016/j.diabres.2020.108604] [PMID: 33338553]
[16]
Almdal T, Almdal K, Hemmingsen B, Hornum M. Clinical benefit of treatment of early Posttransplant Hyperglycemia and Post Transplantation diabetes following solid organ transplantation. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020194202
[17]
Sterne JAC, Hernan MA, Reeves BC, et al. ROBINS-I: A tool for assessing risk of bias in non-randomized studies of intervention. BMJ 2016; 355: i4919.
[http://dx.doi.org/10.1136/bmj.i4919]
[http://dx.doi.org/10.1136/bmj.i4919]
[18]
Sterne JAC, Savović J, Page MJ, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.
[http://dx.doi.org/10.1136/bmj.l4898] [PMID: 31462531]
[http://dx.doi.org/10.1136/bmj.l4898] [PMID: 31462531]
[20]
Kim HJ, Jung SH, Kim JJ, et al. New-onset diabetes mellitus after heart transplantation incidence, risk factors and impact on clinical outcome. Circ J 2017; 81(6): 806-14.
[http://dx.doi.org/10.1253/circj.CJ-16-0963] [PMID: 28344200]
[http://dx.doi.org/10.1253/circj.CJ-16-0963] [PMID: 28344200]
[21]
Munshi VN, Saghafian S, Cook CB, Eric Steidley D, Hardaway B, Chakkera HA. Incidence, risk factors, and trends for postheart transplantation Diabetes Mellitus. Am J Cardiol 2020; 125(3): 436-40.
[http://dx.doi.org/10.1016/j.amjcard.2019.10.054] [PMID: 31812226]
[http://dx.doi.org/10.1016/j.amjcard.2019.10.054] [PMID: 31812226]
[22]
Ollech JE, Kramer MR, Peled N, et al. Post-transplant diabetes mellitus in lung transplant recipients: incidence and risk factors. Eur J Cardiothorac Surg 2008; 33(5): 844-8.
[http://dx.doi.org/10.1016/j.ejcts.2008.01.050] [PMID: 18339554]
[http://dx.doi.org/10.1016/j.ejcts.2008.01.050] [PMID: 18339554]
[23]
Hackman KL, Bailey MJ, Snell GI, Bach LA. Diabetes is a major risk factor for mortality after lung transplantation. Am J Transplant 2014; 14(2): 438-45.
[http://dx.doi.org/10.1111/ajt.12561] [PMID: 24401019]
[http://dx.doi.org/10.1111/ajt.12561] [PMID: 24401019]
[24]
Kuo HT, Sampaio MS, Ye X, Reddy P, Martin P, Bunnapradist S. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the organ procurement and transplant network/united network for organ sharing database. Transplantation 2010; 89(9): 1134-40.
[http://dx.doi.org/10.1097/TP.0b013e3181d2fec1] [PMID: 20386364]
[http://dx.doi.org/10.1097/TP.0b013e3181d2fec1] [PMID: 20386364]
[25]
Ling Q, Xu X, Xie H, et al. New‐onset diabetes after liver transplantation: a national report from China Liver Transplant Registry. Liver Int 2015; 36(5): 705-12.
[http://dx.doi.org/10.1111/liv.13042] [PMID: 26681557]
[http://dx.doi.org/10.1111/liv.13042] [PMID: 26681557]
[26]
Aravinthan AD, Fateen W, Doyle AC, et al. The impact of preexisting and post-transplant diabetes mellitus on outcomes following liver transplantation. Transplantation 2019; 103(12): 2523-30.
[http://dx.doi.org/10.1097/TP.0000000000002757] [PMID: 30985734]
[http://dx.doi.org/10.1097/TP.0000000000002757] [PMID: 30985734]
[27]
Lieber SR, Lee RA, Jiang Y, et al. The impact of post‐transplant diabetes mellitus on liver transplant outcomes. Clin Transplant 2019; 33(6): e13554.
[http://dx.doi.org/10.1111/ctr.13554] [PMID: 30927288]
[http://dx.doi.org/10.1111/ctr.13554] [PMID: 30927288]
[28]
Munshi VD, Saghafian S, Cook CB, et al. Comparison of post-transplantation diabetes mellitus incidence and risk factors between kidney and liver transplantation people. PLoS One 2020; 15(1)e0226873
[http://dx.doi.org/10.1371/journal.pone.0226873]
[http://dx.doi.org/10.1371/journal.pone.0226873]
[29]
Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008; 3(3): 814-21.
[http://dx.doi.org/10.2215/CJN.04681107] [PMID: 18322046]
[http://dx.doi.org/10.2215/CJN.04681107] [PMID: 18322046]
[30]
Demirci MS, Toz H, Yılmaz F, et al. Risk factors and consequences of post-transplant diabetes mellitus. Clin Transplant 2010; 24(5): E170-7.
[http://dx.doi.org/10.1111/j.1399-0012.2010.01247.x] [PMID: 20384711]
[http://dx.doi.org/10.1111/j.1399-0012.2010.01247.x] [PMID: 20384711]
[31]
Kuo HT, Sampaio MS, Vincenti F. Bunna Prist S. Associations of pretransplant diabetes, new-onset diabetes after transplantation, and acute rejection with transplant outcomes: An Analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) Database. Am J Kidney Dis 2010; 56: 1127-39.
[http://dx.doi.org/10.1053/j.ajkd.2010.06.027] [PMID: 20934793]
[http://dx.doi.org/10.1053/j.ajkd.2010.06.027] [PMID: 20934793]
[32]
Dienemann T, Fujii N, Li Y, et al. Long-term patient survival and kidney allograft survival in post-transplant diabetes mellitus: a single-center retrospective study. Transpl Int 2016; 29(9): 1017-28.
[http://dx.doi.org/10.1111/tri.12807] [PMID: 27284760]
[http://dx.doi.org/10.1111/tri.12807] [PMID: 27284760]
[33]
Hecking M, Haidinger M, Döller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol 2012; 23(4): 739-49.
[http://dx.doi.org/10.1681/ASN.2011080835] [PMID: 22343119]
[http://dx.doi.org/10.1681/ASN.2011080835] [PMID: 22343119]
[34]
Werzowa J, Hecking M, Haidinger M, et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. Transplantation 2013; 95(3): 456-62.
[http://dx.doi.org/10.1097/TP.0b013e318276a20e] [PMID: 23380864]
[http://dx.doi.org/10.1097/TP.0b013e318276a20e] [PMID: 23380864]
[35]
Haidinger M, Werzowa J, Hecking M, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation-a randomized, double-blind, placebo-controlled trial. Am J Transplant 2014; 14(1): 115-23.
[http://dx.doi.org/10.1111/ajt.12518] [PMID: 24279801]
[http://dx.doi.org/10.1111/ajt.12518] [PMID: 24279801]
[36]
Halden TAS, Kvitne KE, Midtvedt K, et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 2019; 42(6): 1067-74.
[http://dx.doi.org/10.2337/dc19-0093] [PMID: 30862658]
[http://dx.doi.org/10.2337/dc19-0093] [PMID: 30862658]
[37]
Alnasrallah B, Goh TL, Chan LW, Manley P, Pilmore H. Transplantation and diabetes (Transdiab): A pilot randomised controlled trial of metformin in impaired glucose tolerance after kidney transplantation. BMC Nephrol 2019; 20(1): 147.
[http://dx.doi.org/10.1186/s12882-019-1321-2] [PMID: 31035960]
[http://dx.doi.org/10.1186/s12882-019-1321-2] [PMID: 31035960]
[38]
Kuningas K, Driscoll J, Mair R, et al. Comparing glycemic benefits of active versus passive lifestyle intervention in kidney allograft recipients (Caviar): A randomized controlled trial Nephrology dialysis transplantation. Transpl Int 2020; 104: 1491-9.
[http://dx.doi.org/10.1097/TP.0000000000002969] [PMID: 31568390]
[http://dx.doi.org/10.1097/TP.0000000000002969] [PMID: 31568390]
[39]
a) American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33(S1): S62-9.;
b) Correction to the 2010 report on the diagnosis and classification of diabetes. Diabetes Care 2010; 33(4)e57 [Erratum]
[http://dx.doi.org/10.2337/dc10-S062]
b) Correction to the 2010 report on the diagnosis and classification of diabetes. Diabetes Care 2010; 33(4)e57 [Erratum]
[http://dx.doi.org/10.2337/dc10-S062]
[40]
Ojo A. A clinical trial to prevent New Onset Diabetes After Transplantation (ITP-NODAT) ClinicalTrialsGov 2019. Available from: clinicaltrials.gov/ct2/show/study/NCT01683331?term=Posttransplantation+diabetes%2C+ojo&draw=2&rank=1
[41]
Schwaiger E, Krenn S, Kurnikowski A, et al. Early postoperative basal insulin therapy versus standard of care for the prevention of diabetes mellitus after kidney transplantation. J Am Soc Nephrol 2021; 32(8): 2083-98.
[http://dx.doi.org/10.1681/ASN.2021010127] [PMID: 34330770]
[http://dx.doi.org/10.1681/ASN.2021010127] [PMID: 34330770]
[42]
Topitz D, Schwaiger E, Frommlet F, Werzowa J, Hecking M. Cardiovascular events associate with diabetes status rather than with early basal insulin treatment for the prevention of post-transplantation diabetes mellitus. Nephrol Dial Transplant 2020; 35(3): 544-6.
[http://dx.doi.org/10.1093/ndt/gfz244] [PMID: 31803915]
[http://dx.doi.org/10.1093/ndt/gfz244] [PMID: 31803915]
[43]
Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycemic control, and macrovascular and microvascular outcomes in people with type 2 diabetes: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. BMJ 2011; 343: d6898.
[http://dx.doi.org/10.1136/bmj.d6898] [PMID: 22115901]
[http://dx.doi.org/10.1136/bmj.d6898] [PMID: 22115901]
[44]
Gyldenkerne C, Knudsen JS, Olesen KKW, et al. Nationwide trends in cardiac risk and mortality in patients with incident type 2 diabetes. A Danish Cohort Study. Diabetes Care 2021; 44(10): 2353-60.
[http://dx.doi.org/10.2337/dc21-0383] [PMID: 34380704]
[http://dx.doi.org/10.2337/dc21-0383] [PMID: 34380704]
[45]
Holdaas H, Fellstrøm B, Jardine A, et al. Effect of fluvastatin on cardiac outcomes in renal transplant: A multicenter, randomized, placebo controlled trial. Lancet 2003; 361(9374): 2024-31.
[http://dx.doi.org/10.1016/S0140-6736(03)13638-0]
[http://dx.doi.org/10.1016/S0140-6736(03)13638-0]
[46]
Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Libr 2014; 2015(1)CD005019
[http://dx.doi.org/10.1002/14651858.CD005019.pub4] [PMID: 24470059]
[http://dx.doi.org/10.1002/14651858.CD005019.pub4] [PMID: 24470059]
[47]
Cholesterol Treatment Trialists' (CTT). Collaboration Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomized trials of statins: A meta-analysis. Lancet 2008; 371: 117-25.
[http://dx.doi.org/10.1016/S0140-6736(08)60104-X]
[http://dx.doi.org/10.1016/S0140-6736(08)60104-X]
[48]
Outcomes IG. (KDIGO) clinical practice guideline on the monitoring, management, and treatment of kidney transplant recipients. Am J Transplant 2009; 9: S1-S155.
[http://dx.doi.org/10.1111/j.1600-6143.2009.02834.x]
[http://dx.doi.org/10.1111/j.1600-6143.2009.02834.x]
[49]
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4): 311-22.
[http://dx.doi.org/10.1056/NEJMoa1603827] [PMID: 27295427]
[http://dx.doi.org/10.1056/NEJMoa1603827] [PMID: 27295427]
[50]
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117-28.
[http://dx.doi.org/10.1056/NEJMoa1504720] [PMID: 26378978]
[http://dx.doi.org/10.1056/NEJMoa1504720] [PMID: 26378978]
